Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of TranS1, Inc. (“TranS1” or the “Company”) (NASDAQGM:TSON), concerning whether the company and certain of its officers and directors have violated federal securities laws. On October 17, 2011, TranS1, the Wilmington-based medical device company, announced in a regulatory filing that on or about October 6, 2011, the federal government subpoenaed documents from them. The subpoena from the Department of Health and Human Services' Office of Inspector General is "under the authority of the federal health care fraud and false claims statutes," the company said in a filing with the Securities and Exchange Commission. According to the filing, the subpoena seeks documents from January 1, 2008, through October 6, 2011. Following this news, the Company’s shares plummeted nearly 40%. If you are aware of any facts relating to this investigation, or purchased shares of TranS1, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate work, private securities offerings, and securities arbitration.